Centes­sa to take nar­colep­sy drug in­to Phase 2 af­ter no sign of side ef­fects that doomed ear­li­er com­peti­tor

Centes­sa Phar­ma­ceu­ti­cals plans to take its orex­in re­cep­tor 2 ag­o­nist in­to mid-stage test­ing for nar­colep­sy af­ter a Phase 1 study showed signs of ef­fi­ca­cy. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER